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Krüppel-like factor 5 (KLF5) regulatesmultiple biologic processes. Its function in tumorigenesis appears contradictory though,
showingboth tumorsuppressor and tumorpromotingactivities. In this study,weexaminedwhetherandhowKlf5 functions in
prostatic tumorigenesis usingmicewith prostate-specific deletion of Klf5 andphosphatase and tensin homolog (Pten), both of
which are frequently inactivated in human prostate cancer. Histologic analysis demonstrated that when one Pten allele was
deleted, which causes mouse prostatic intraepithelial neoplasia (mPIN), Klf5 deletion accelerated the emergence and
progression of mPIN. When both Pten alleles were deleted, which causes prostate cancer, Klf5 deletion promoted tumor
growth, increased cell proliferation, and causedmore severemorphologic andmolecular alterations. Homozygousdeletionof
Klf5wasmoreeffective thanhemizygousdeletion.Unexpectedly,whilePtendeletionaloneexpandedbasal cell population ina
tumor as reported, Klf5 deletion in the Pten-null background clearly reduced basal cell populationwhile expanding luminal cell
population.Global geneexpressionprofiling, pathwayanalysis, andexperimental validation indicate thatmultiplemechanisms
could mediate the tumor-promoting effect of Klf5 deletion, including the up-regulation of epidermal growth factor and its
downstream signaling molecules AKT and ERK and the inactivation of the p15 cell cycle inhibitor. KLF5 also appears to
cooperate with several transcription factors, including CREB1, Sp1, Myc, ER and AR, to regulate gene expression.
These findings validate the tumor suppressor function of KLF5. They also yield a mouse model that shares two
common genetic alterations with human prostate cancer—mutation/deletion of Pten and deletion of Klf5.
Neoplasia (2014) 16, 883–899Introduction
Prostate cancer is a common malignancy and a leading cause of
cancer-related deaths. As in many other types of cancers, prostatic
carcinogenesis is a multistep process that results from theaccumulation of multiple genetic and epigenetic alterations.
Identification and functional characterization of the cancer-causing
alterations provides important molecular insights into how a cancer
forms and improves cancer detection and treatment. While a numberImaging Shared Resource, the Emory Integrated Genomics Core, the Biostatistics and
Bioinformatics SharedResource ofWinshipCancer Institute of EmoryUniversity, andNIH/
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884 Klf5 deletion promotes prostatic tumorigenesis Xing et al. Neoplasia Vol. 16, No. 11, 2014of genes have been identified with genetic/epigenetic alterations and
causal roles in cancer, more such genes remain to be discovered and
functionally examined. Chromosomal deletion is one of the most
common genetic alterations in human cancer, and one common
consequence of chromosomal deletion is the inactivation of tumor
suppressor genes during carcinogenesis [1]. In prostate cancer, a
number of commonly deleted chromosomal regions have been
mapped, and one or more tumor suppressor genes have been
identified for some of the commonly deleted regions, including
phosphatase and tensin homolog (PTEN) from 10q22, NKX3-1 from
8p21, and ATBF1 from 16q22 [1–4]. Key evidence for the tumor
suppressor activity of a gene is the induction of neoplastic alteration
after its deletion in mice, as seen for a number of tumor suppressor
genes including Pten, Nkx3-1, p53, Rb, and Smad4 [5–8].
Krüppel-like factor 5 (KLF5, also known as BTEB2), encoding a
basic transcription factor and located at the q21 band of human
chromosome 13 (13q21), centers the second most frequently deleted
chromosomal region in human prostate cancer, as revealed by
comparative genomic hybridization studies [1,9,10]. The deletion is
exclusively hemizygous, causing the haploinsufficiency of KLF5
during cancer development [10–12]. In addition, KLF5 protein is
degraded by the ubiquitin proteasome pathway, and one E3 ubiquitin
ligase that degrades KLF5, WWP1, is amplified and overexpressed in
human prostate and breast cancers, causing excessive protein
degradation and functional insufficiency of KLF5 [13–15]. These
findings indicate that KLF5 is frequently inactivated during human
carcinogenesis and thus could be a tumor suppressor gene, and some
functional studies indeed support a tumor suppressor function of
KLF5. For example, KLF5 can inhibit the proliferation of epithelial
cells including some cancer cell lines in culture [10,11,16,17] and
suppresses the tumorigenesis of human prostate cancer cell lines in
nude mice [18]. However, KLF5 has also been demonstrated to
promote the tumorigenesis of a bladder cancer cell line in a xenograft
model [19] and mediate or be necessary for intestinal tumorigenesis
induced by other oncogenic events in genetically modified mice [20–23].
Our recent study indicates that KLF5 indeed can be both tumor
suppressing and tumor promoting in the same cancer cell lines in
xenograft models and that the acetylation status of KLF5 determines its
function in tumorigenesis [24]. Nevertheless, whether frequent deletion
of KLF5 in human prostate cancer has any functional consequences
remains uncertain, because our previous study demonstrated that, in
mouse prostates, hemizygous deletion of Klf5 alone increases cell
proliferation and induces hyperplasia but does not cause neoplastic
alterations such as mouse prostatic intraepithelial neoplasia (mPIN) or
tumor [25], and homozygous deletion of Klf5 causes apoptosis rather
than increases cell proliferation and does not induce any noticeable
histologic alterations [25]. Therefore, a tumor suppressor function has not
been established for KLF5 using genetically modified mice.
PTEN, a protein and lipid phosphatase that negatively regulates
phosphoinositide 3-kinase (PI3K)/AKT oncogenic signaling, is a tumor
suppressor that undergoes frequent mutations and deletions in human
tumors including prostate cancer [26]. Activation of PI3K/AKT
signaling by PTEN inactivation stimulates cell cycle progression and
survival and, consequently, induces tumorigenesis [27], as demonstrat-
ed by the induction of prostate cancer after Pten homozygous deletion
in mice [5]. Similar to KLF5, chromosomal deletion is also a common
mechanism for the loss of PTEN function in different types of
human cancers including prostate cancer [1,26,28]. As two of the
most commonly deleted genetic loci in human prostate cancer,deletion of both PTEN and KLF5 can occur in the same tumors.
For example, the commonly used human prostate cancer cell line
LNCaP has the deletion of both PTEN and KLF5 [10,29]. It is
thus possible that simultaneous deletions of KLF5 and PTEN
cooperate to initiate and promote tumorigenesis.
In this study, we tested whether and how simultaneous deletions of
Klf5 and Pten interact to initiate and promote prostatic tumorigenesis
in mice. We found that deletion of Klf5 accelerated the emergence and
progression of mPIN induced by hemizygous deletion of Pten. In the
Pten-null background, Klf5 deletion increased cell proliferation and
promoted tumorigenesis, as indicated by more severe morphology.
Interestingly, while Pten deletion alone increased the ratio of basal to
luminal cells in a tumor as previously reported, Klf5 deletion in the
Pten-null background increased luminal but diminished basal cell
population in tumors. Mechanistically, Klf5 deletion dysregulated
a large number of genes and signaling pathways, including the up-
regulation of extracellular growth factor, epidermal growth factor
(EGF), and its downstream signaling molecules AKT and
extracellular signal-regulated kinases (ERK) and the inhibition of
the p15 cell cycle inhibitor. Several transcription factors appear to
cooperate with KLF5 to function in the prostate. These findings
provide in vivo evidence for the tumor suppressor activity of KLF5.
They also provide a mouse model of prostate cancer that shares two
common genetic alterations with human prostate cancer.
Materials and Methods
Mouse Strains
TheKlf5 floxedmouse strain, in which the genomic DNA from exon
2 to exon 3 ofKlf5 is flanked by loxP sites, was generated as described in
our previous study [25]. The PB-Cre4 transgenic mouse strain, where
expression of Cre recombinase is driven by the prostatic epithelial
specific probasin promoter [30], was purchased from the NCI Mouse
Models of Human Cancers Consortium (MMHCC, Frederick, MD;
Cat. No. 01XF5). Pten floxed mice were purchased from the Jackson
Laboratory (Bar Harbor, ME; Cat. No. 004597). All mice were
maintained in a mixed background of C57BL/6 J and 129Sv/J.
Mouse Breeding and Genotyping
The breeding strategy is shown in Figure 1A. Floxed-Klf5 mice
(Klf5flox/flox) were crossed with floxed-Pten mice (Pten flox/flox), and the
F1mice were then crossed with PB-Cre4 mice to generate the following
six desired genotypes: Cre+/Ptenflox/wt/Klf5wt/wt, Cre+/Ptenflox/wt/Klf5flox/wt,
Cre+/Ptenflox/wt/Klf5flox/flox, Cre+/Ptenflox/flox/Klf5wt/wt, Cre+/Ptenflox/flox/
Klf5flox/wt, and Cre+/Ptenflox/flox/Klf5flox/flox.
All mice were toe-clipped for identification and tail-clipped to
collect tissues for genotyping at age 10 to 14 days. Freshly dissected
tissues were washed in phosphate-buffered saline (PBS) to clean blood
and incubated overnight at 56°C with tissue lysis buffer (100 mM
Tris-HCl, 5 mM EDTA, 200 mM NaCl, 0.2% sodium dodecyl
sulfate, 500 μg/ml proteinase K, pH 8.0) to release DNA. Diluted
tissue lysates were used as templates for polymerase chain reaction
(PCR)–based genotyping. PCR conditions were previously described
[31]. Primer sequences and sizes of PCR products for genotyping the
different genes are listed in Table S1.
RNA Extraction and Real-Time PCR Assay
For mouse tissues, freshly dissected prostate tissues were
immediately immersed into the RNAlater solution (Qiagen,
Valencia, CA) for at least 16 hours at 4°C. Total RNA was then
Figure 1. Breeding strategy and deletion confirmation for prostatic knockout of Klf5 and Pten. (A) Schematic of breeding design for the
generation of mice with all six desired genotypes of Klf5 and Pten using mouse strains of floxed Klf5 (Klf5F/F), floxed Pten (PtenF/F) ,and PB-
Cre4. F andW indicate floxed andwild-type alleles, respectively. (B and C) Detection of Klf5 protein expression by IHC staining in 6-month-old
APs (B) and Klf5mRNA expression by real-time RT-PCR in the whole prostate of 6-month-old mice (C) with different Klf5 deletion status and
Pten homozygous deletion. (D and E) Detection of Pten protein expression by IHC staining in 6-month-old APs (D) and PtenmRNAexpression
by real-time RT-PCR in thewhole prostate of 6-month-oldmice (E) with different Pten deletion status. + and− indicate wild-type and deleted
Klf5 or Pten alleles, respectively; * and ** indicate P b .05 and P b .01, respectively, based on Student's t test.
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manufacturer’s instructions. For cultured cells, total RNA was
isolated using the TRIzol reagent (Invitrogen, Carlsbad, CA)
following the procedures established previously [32]. The first
strand of cDNA was synthesized using the iScript cDNA synthesis
kit (Bio-Rad, Hercules, CA).
Real-time reverse transcription (RT)–PCR was performed using the
SYBRPremix Ex Taq reagent (Takara Otsu, Shiga, Japan) with the ABI
Prism 7500 Real-Time PCR System (Applied Biosystems, Foster City,CA). The 2(−ΔΔCt) methodwas used to calculate the relative fold change
for a gene’s expression, with the expression level of glyceraldehyde 3-
phosphate dehydrogenase (GAPDH) as an internal control. Primers for
real-time PCR assays are listed in Table S1.
Microarray-Based Expression Profiling and Signaling Pathway
Analysis
The microarray experiment was performed at the Emory Integrated
Genomics Core using standard procedures. Briefly, total RNA was
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with the genotype of Pten−/−;Klf5+/+ or Pten−/−;Klf5−/−. The quality of
total RNA was confirmed using an Agilent Bioanalyzer (Agilent
Technologies, Palo Alto, CA). After synthesis from the same amount of
total RNA, the cDNA library for a tissue sample was hybridized to the
Affymetrix Mouse Gene 1.0 ST Array, which covers 28,853 genes with
approximately 27 probes per gene spread across the full length of each
gene. Hybridization and washing and staining of probe arrays were
performed according toAffymetrix’s protocol. GeneChips were scanned
using the Affymetrix 3000 scanner and images were converted to digital
data, which were then analyzed by using the GeneSpring GX program
(Agilent Technologies). The initial list of genes was generated with the
preliminary data using mean polish and robust multi-array average
(RMA) with GC content adjustment.
Genes were sorted by their P values between the wild-type Klf5 and
Klf5-null groups, and those with P b .05 were considered differentially
expressed. After ranking by the fold change of expression, differentially
expressed genes were categorized into the following seven groups: 1.5 to
2.0, 2.0 to 2.5, 2.5 to 3.0, 3.0 to 4.0, 4.0 to 5.0, 5.0 to 10, and N10 fold
change of expression. For each group, four to seven genes were chosen
and subjected to real-time RT-PCR to validate their differential
expression with four to eight RNA samples, including the four used for
microarray hybridization. On the basis of published studies using the
same gene arrays [33–35] and the validation of 31 of 33 genes, we set the
threshold of fold change to 1.5 to establish the list of differentially
expressed genes for pathway and ontology analyses. The original
microarray data have been deposited in National Center for
Biotechnology Information (NCBI)’s Gene Expression Omnibus
database and are accessible through Gene Expression Omnibus Series
Accession No. GSE58719.
Differentially expressed genes and their expression levels were
uploaded into the web-based MetaCore program (http://
thomsonreuters.com/metacore), and different algorithms were run
with MetaCore database to identify or build signaling pathways, gene
ontology (GO)–based functional processes, and molecular networks
that are modulated by Klf5 deletion. For each of the 586 genes
identified as prostate cancer–related genes by the Disease (by
biomarkers) Ontology of MetaCore, a PubMed search with a gene’s
name and “prostate cancer” as search terms indicated that 203 of the
genes had been studied in prostate cancer. The publications were
evaluated to identify those genes that have been shown to functionally
impact prostate cancer cell behavior [proliferation, apoptosis,migration,
epithelial-to-mesenchymal transition (EMT), metastasis, and so on],
undergo promoter methylation, or have expression abnormalities that
are associated with clinical or pathologic characteristics of prostate
cancer. The resultant 172 genes and their normalized log2 values of
intensity differences between Klf5 wild-type and Klf5-null groups were
then subjected to the R software to generate a heat map.
Genes dysregulated byKlf5 deletion in this study were also compared
to those identified in previous studies [24,33–35] to identify the genes
that are regulated by Klf5 in different tissues or experimental systems.
Histopathologic Analysis
Mice with different Klf5 and Pten deletion status were sacrificed at
various time points (4, 6, 9, 12, 15, and 18 months for the Pten+/−
group and 2, 4, and 6 months for the Pten−/− group), and prostates
were freshly collected and dissected in cold PBS. Tissues for
histopathologic analysis were fixed in 3.7% neutral buffered
formaldehyde overnight. Fixed tissues were then embedded inparaffin, sectioned at 5-μm thickness, and stained with hematoxylin
and eosin (H&E) following standard protocols.
Pathologic diagnosis was performed by pathologists led byDr Robert
D. Cardiff through a paid service at the Center for Comparative
Medicine, Department of Pathology, University of California at Davis.
Published guidelines were followed [36,37].
Immunohistochemical and Immunofluorescence Staining
For immunohistochemical (IHC) staining, tissue sections on glass
slides were deparaffinized in xylene, rehydrated in graded ethanol
solutions, and washed in tap water. Antigen retrieval was performed
by boiling the slides in a pressure cooker for 3 minutes in a citrate
buffer (10 mM trisodium citrate, pH 6.0). After 10-minute treatment
with 3% H2O2, tissue sections were then blocked with 5% normal
goat serum in Tris-buffered saline with 0.1% Tween-20 for 1 hour at
room temperature, incubated with primary antibodies at 4°C
overnight, and then incubated with EnVision Polymer-HRP
secondary antibodies (Dako, Glostrup, Denmark) for 30 minutes at
room temperature. After the application of DAB chromogen, tissue
sections were stained with hematoxylin, dehydrated, and mounted.
The slides were then scanned with a Hamamatsu NanoZoomer
scanner (Hamamatsu Corporation, Bridgewater, NJ). For some
proteins, cell numbers were counted to determine the positive rate.
For immunofluorescence (IF) staining, the same procedures of
deparaffinization, rehydration, and antigen retrieval were followed.
Tissue sections were then incubated with the blocking solution (10%
normal goat serum and 1%BSA in PBS) for 1 hour at room temperature,
with primary antibodies at 4°C overnight, and with secondary antibodies
(Alexa Fluor dyes; Invitrogen) for 30minutes at room temperature. After
4',6-diamidino-2-phenylindole (DAPI) staining for nuclei, slides were
mounted with anti-photobleaching mounting medium. Multichannel
pictures were taken with a Zeiss Axioplan 2 Wide-Field Microscope
(Carl Zeiss Microscopy, Thornwood, NY).
The primary antibodies used in this study (IHC or IF) and dilutions
were given as follows: rabbit anti-KLF5 (IHC, 1:6000 dilution) [25],
rabbit anti-PTEN (Cell Signaling Technology, Danvers, MA; IHC,
1:100), rabbit anti-Ki67 (Thermo Fisher Scientific,Waltham,MA; IHC,
1:200), rabbit anti–phospho-Akt (Cell Signaling Technology; IHC,
1:150), mouse anti–phospho-Erk1/2 (Cell Signaling Technology;
IHC, 1:200), rabbit anti–phospho-mammalian target of rapamycin
(mTOR) (Cell Signaling Technology; IHC, 1:100), rabbit anti–
phospho-S6 (Cell Signaling Technology; IHC, 1:200), rabbit anti-
p15/INK4B (Cell Signaling Technology; IHC, 1:1000), rabbit anti-CK5
(Covance, Princeton, NJ; IHC, 1:1000; IF, 1:200), mouse anti-Ck14
(Thermo Fisher Scientific; IF, 1:200), mouse anti-p63 (Santa Cruz
Biotechnology, Santa Cruz, CA; IF, 1:100), rabbit anti-Ck18 (GeneTex,
Irvine,CA; IHC,1:1500; IF, 1:400),mouse anti–smoothmuscle actin (Sma;
Sigma-Aldrich, St Louis, MO; IHC, 1:5000), rabbit anti-EGF (Abcam,
Cambridge,MA; IHC, 1:400), and rabbit anti–phospho–Egf receptor (Egfr)
Y1068 (Cell Signaling Technology; IHC, 1:100).Knockdown of KLF5 and PTEN by RNA Interference
The PNT2 human prostate luminal cell line, originated from SV40-
immortalized normal prostate epithelium, was purchased from Sigma and
cultured in RPMI 1640 supplemented with 10% FBS. PNT2 cells were
transfected with siRNAs against KLF5, PTEN, or the control with the X-
tremeGENEHP transfection reagent (Roche,Nutley,NJ) to knock down
the expression of KLF5 or PTEN. Sequences of siRNAs were given as
follows: siKLF5, AAGCUCACCUGAGGACUCATT [38]; siPTEN,
Table 1. Numbers of Mice with Hyperplasia (HP) and mPIN in the AP, DP, LP, and VP at
Different Ages (Months) with Hemizygous Deletion of Pten and Different Klf5 Deletion Status
Klf5 Deletion AP DP LP VP Total
Mice
HP mPIN HP mPIN HP mPIN HP mPIN
4 to 6 months
+/+ 2 1 3 0 2 1 3 0 3
+/− 8 0 3 5 1 7 8 0 8
−/− 5 2 3 4 3 4 7 0 7
9 to 12 months
+/+ 8 1 7 1 5 2 7 1 9
+/− 4 8 2 10** 2 10* 11 1 12
−/− 6 3 0 9** 2 7 7 2 9
15 to 18 months
+/+ 4 7 0 11 4 6 11 0 11
+/− 2 13 0 15 4 11 13 2 15
−/− 3 7 1 9 1 8 8 1 10
All ages
+/+ 14 9 10 12 11 9 21 1 23
+/− 14 21 5 30* 7 28* 32 3 35
−/− 14 12 4 22* 6 19 22 3 26
Note: Chi-square analysis was used to determine the statistical significance of a phenotype caused by
Klf5 deletion. + and − indicate the presence and absence, respectively, of a Klf5 allele in the prostate.
*P b .05; **P b .01.
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CUCCGAACGUGUCACGUTT (Thermo Fisher Scientific).
Western Blot Analysis
Western blot analysis was performed following previously established
procedures [32]. The antibody against human KLF5 was prepared as
previously described [14], and those against other proteins are given
as follow: rabbit anti-PTEN, rabbit anti–phospho-AKT, rabbit anti–
phospho-ERK, rabbit anti-AKT, rabbit anti-ERK, and rabbit anti–
phospho-S6 were from Cell Signaling Technology; and rabbit anti–β-
actin, rabbit anti-p15, and rabbit anti-mouse Klf5 were from Sigma,
Santa Cruz Biotechnology, andMillipore (Temecula, CA), respectively.
Detection of Apoptosis by the Terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) Assay
The TumorTACS In Situ Apoptosis Detection Kit (Trevigen,
Gaithersburg, MD) was used for the TUNEL assay following
manufacturer’s instruction. Formalin-fixed prostate sections from
6-month-old mice were stained in triplicate for each genotype.
Slides were then scanned, and the number of apoptotic cells and the
number of total cells in the anterior and DPs were counted using
ImageJ software to determine the percentage of apoptotic cells.
Statistical Analysis
Statistical analyses were performed using the GraphPad Instat
statistical computer program (GraphPad Software, Inc, La Jolla, CA).
One-way analysis of variance was used to determine statistical
differences among groups in the analysis of Ki67-positive rate, while
the Chi-square analysis was used for differences in phenotype changes
among the three Klf5 genotypes in Table 1. P values less than .05
were considered statistically significant.
Results
Simultaneous Knockout of Pten and Klf5 in Mouse Prostates
Three strains of mice, including floxed Klf5, floxed Pten, and PB-
Cre4, were used to generate the following six desired genotypes: Cre+/
Ptenflox/wt/Klf5wt/wt, Cre+/Ptenflox/wt/Klf5flox/wt, Cre+/Ptenflox/wt/Klf5-flox/flox, Cre+/Ptenflox/flox/Klf5wt/wt, Cre+/Ptenflox/flox/Klf5 flox/wt, and
Cre+/Ptenflox/flox/Klf5flox/flox (Figure 1A). These mice were divided
into two groups according to Pten deletion status, i.e., hemizygous
deletion (Pten+/−) and homozygous deletion (Pten−/−; Figure 1A). All
three strains of mice have been successfully used in previous studies
[5,25], and efficient gene knockout in the prostate was confirmed by
examining the expression of Pten and Klf5 at the mRNA and protein
levels by real-time RT-PCR and IHC staining. The mRNA levels for
both Klf5 and Pten were reduced by about half in tissues with
hemizygous deletion and the reduction was dramatic in tissues with
homozygous deletion (Figure 1, C and E). The protein expression of
Klf5 or Pten was also significantly decreased on genomic deletion of the
respective gene (Figures 1, B and D, and W1, and data not shown).
These results validated the knockout system for further analyses.
Klf5 Deletion Accelerated the Development and Severity of
mPIN Induced by Pten Hemizygous Deletion
Deletion of one Pten allele causes mPIN [5], so we first examined
whether Klf5 deletion affects mPIN development induced by
hemizygous deletion of Pten. At 4 to 6 months of age, prostates with
Pten hemizygous deletion alone (Pten+/−/Klf5+/+) began to show
scattered hyperplasia, but no mPIN was noticeable. Simultaneous
deletion of Klf5, either of one allele (Pten+/−/Klf5+/−) or both alleles
(Pten+/−/Klf5−/−), caused the appearance of low-grade mPIN in both
DP and lateral prostate (LP), which was characterized bymultiple layers
of larger cells with abundant pale cytoplasm (Figure 2, panels at the left).
At 9 to 12 months of age, while single allele deletion of Pten (Pten+/−/
Klf5+/+) caused low-grade mPIN (grades I and II), simultaneous
deletion of Klf5 (Pten+/−/Klf5+/− and Pten+/−/Klf5−/−) caused high-
grade (HG) mPIN (grades III and IV), as indicated by the filling of the
lumenwith excess cells that had an increased nucleus-to-cytoplasm ratio
and small intraepithelial blood vessels (Figure 2, panels in the middle).
At 15 to 18months of age, while HGmPIN developed in some but not
all prostates with Pten hemizygous deletion alone (Pten+/−/Klf5+/+),
inactivation of one or both Klf5 alleles (Pten+/−/Klf5+/− and Pten+/−/
Klf5−/−) caused more severe HG mPIN with higher nucleus-to-
cytoplasm ratios. The large cell pattern seen with deletions of both Pten
and Klf5 was typical for AKT/PTEN-related tumors, further indicating
a more severe cancer-related phenotype (Figure 2, panels at the right).
We compared the incidence of mPIN between prostates with and
without the deletion of Klf5 and found that deletion of one or both
Klf5 alleles caused a statistically significant increase in the incidence
of mPIN in mice 9 to 12 months old (Table 1). When all age groups
were combined, the difference was still statistically significant
(Table 1). We also noticed that Klf5 deletion caused more severe
abnormalities in the DP and LP (Figure 2) but less in the anterior
prostate (AP) and ventral prostate (VP). In addition, few differences
were noticeable between hemizygous and homozygous deletions of
Klf5 in the development and progression of mPIN (Figure 2),
although hemizygous deletion of Klf5 only decreased Klf5 expression
in some cells (Figure S1), indicating that Klf5 is haploinsufficient and
its haploinsufficiency is sufficient for the acceleration of Pten
deletion–induced mPIN and related alterations.
Klf5 Deletion Promoted Pten Deletion–Initiated Prostatic
Tumorigenesis and Disrupted the Luminal Architecture of Tumors
In the original study of Pten deletion in mouse prostates [5], Pten
homozygous deletion caused invasive prostate cancer by the age of 9
weeks. In our study, prostate cancer was not detectable until the age
Figure 2. Deletion of Klf5 accelerates the development and severity
of mPIN induced by hemizygous deletion of Pten. H&E-stained
tissue section images of DPs and LPs at 6, 12, and 18 months with
Klf5 and Pten deletions indicated. + and − indicate wild-type and
deleted Klf5 or Pten alleles, respectively.
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analysis. Compared to prostates with Pten deletion alone at 6 months,
those with both Klf5 and Pten deletions showed an increase in the size
of prostate glands, as visualized in H&E-stained whole gland tissue
section, and Klf5 homozygous deletion showed a more profound
effect than Klf5 hemizygous deletion (Figure 3, upper row).
Histologically, prostate tumors induced by Pten homozygous
deletion alone maintained a luminal architecture (Figure 3), and
necrosis was frequently observed in the center of the tumors, which is
a common feature of HG mPIN and human prostate cancer due to
insufficient nutrients. Interestingly, Klf5 hemizygous deletion
resulted in a decreased luminal space in the prostate gland, and
Klf5 homozygous deletion led to complete filling of the luminal space
with tumor cells and thus the elimination of luminal architecture
(Figure 3, lower panels of the Klf5−/− group). In addition, necroticareas in the tumors were decreased by deletion of one Klf5 allele and
abolished by deletion of both Klf5 alleles. In prostates with
hemizygous Pten deletion, Klf5 deletion–enhanced mPIN mainly
occurred in the DP and LP and the deletions of one or both Klf5
alleles showed similar effects. In contrast, Klf5 deletion caused
morphologic abnormalities in Pten-null prostates in all four lobes,
and deletion of both Klf5 alleles clearly showed a more profound
effect than the deletion of one Klf5 allele (Figure 3).
Molecular Characterization of Architectural Abnormalities in
Prostate Tumors with Deletions of Klf5 and Pten
Since the luminal structure was almost eliminated in prostate tumors
with Klf5 and Pten deletions (Figure 3) and Pten deletion alone caused
the expansion of the basal type of tumor cells, as indicated by positive
staining for theCk5 basal cell marker [39], we further evaluatedwhether
Klf5 deletion altered the luminal architecture of Pten-null tumors. We
examined the expression of molecular markers for major components of
prostatic architecture, including those for luminal cells (Ck18), basal
cells (Ck5 and Ck14), and the fibromuscular stroma (Sma), in 6-
month-old prostate tumors with both Klf5 and Pten deletions.Without
Klf5 deletion, cells in Pten-null prostate tumors were mostly positive for
either a luminal marker (Ck18) or a basal marker (Ck5 or Ck14), and
few cells were positive for both markers (Figure 4, A and B), which is
consistent with the findings in a previous study [39]. When Klf5 was
deleted, the number of basal cells decreased dramatically as
indicated by the staining of Ck5 or Ck14 basal cell marker, while
luminal cells, as indicated by positive staining for the Ck18 luminal
cell marker, expanded and almost occupied the entire tumor
(Figure 4, A and B). In Pten deletion–induced prostate tumors,
expression of p63, a bona fide basal cell marker [40], was still
restricted to basal layers, but Ck5 was expressed in both basal layers
and cancerous acini [39], which was confirmed in our results
(Figure 4C, left row). Interestingly, analysis of tumors with both
Klf5 and Pten deletions demonstrated that, while cells in basal
layers still expressed both p63 and Ck5, almost no tumor cells in
acini expressed Ck5 (Figure 4C), which is different from the effect
of Pten deletion alone. These results indicate that Klf5 deletion
disrupts the ratio of Ck18-positive luminal cells to Ck5-positive
basal cells in Pten deletion–induced prostate tumors.
We also analyzed the expression of Sma, a marker for the layer of
fibromuscular stroma often used to evaluate tumor invasion to the
stroma [17]. Whereas loss of Sma expression with Pten deletion alone
was reported in a previous study [5], our analysis demonstrated that in
prostate tumors with Pten deletion alone, Sma was still expressed, and
the layer of Sma-positive fibromuscular stroma was still intact for an
acinus (Figure 4A, the lower panel in the left two rows).When oneKlf5
allele was deleted (Pten−/−/Klf5+/−), the surrounding smooth muscle
layer became dramatically thinner, although it was still continuous.
When both Klf5 alleles were deleted (Pten−/−/Klf5−/−), the smooth
muscle layer became discontinuous or totally absent for most acini in
tumors (Figure 4A, the lower panel in the right two rows).
Klf5 Deletion Dysregulates a Large Number of Genes
To understand how Klf5 deletion promotes prostate tumorigenesis
initiated by Pten deletion, we performed microarray analysis using
DPs at 6 months with wild-type or homozygous deletion of Klf5 in
the Pten-null background. At 6 months, tumors were larger and had
more severe phenotypic abnormalities (Figure 3). Using the
Affymetrix mouse whole genome chips and associated computer
Figure 3. Deletion of Klf5 promotes the development and severity of prostate tumor induced by homozygous deletion of Pten. Upper row
panels are images of H&E-stained tissue sections from the entire prostate gland at lower magnification, and lower row panels are
magnified images of the boxed areas from the upper row panels. The prostates were from mice at 6 months of age. Note enlarged
prostate glands and significant phenotypic alterations caused by Klf5 deletion. Prostates from two mice are shown for each genotype. +
and − indicate wild-type and deleted Klf5 or Pten alleles, respectively.
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.05) expression difference between Klf5 wild-type and Klf5-null
groups. In previous publications using the same expression chips, a
N1.5-fold change combined with P b .05 has been defined as the
minimum meaningful fold change in the identification of differen-
tially expressed genes [33–35]. Application of the same principle to
our data resulted in a total of 1197 genes, 569 of which were
upregulated and 628 were downregulated (Table S2).
To evaluate the quality of the microarray data, we selected 33 genes
with different degrees of differential expression in the microarray
analysis and performed real-time RT-PCR in four to eight wild-type or
Klf5-null DPs. Differential expression was validated between the two
groups for 31 of the 33 (94%) genes (Figure 5, A and B). In addition,
almost all of the 33 genes showed similar fold changes between
microarray and real-time RT-PCR analyses except for Klf5, which
showed a much more dramatic decrease in the real-time RT-PCR assay
(Figure 5B). These results indicate a good quality of themicroarray data.
As a basic transcription factor, KLF5 could regulate a common set
of genes among different types of tissues. Therefore, we compared our
gene list with published data from other mouse tissues. Among the
genes dysregulated by Klf5 deletion during post-eyelid opening
maturation of mouse corneas [41], 96 upregulated genes and 41
downregulated genes showed the same trends of changes, while 73
genes showed opposite changes compared to our data (Table S3).
Among the available partial list of genes dysregulated by Klf5 deletion
in intestine villus and bladder, a previous study identified 112 genes
that are dysregulated (12 up and 100 down) by Klf5 deletion in both
tissues [35]. Twenty of the downregulated genes but none of the
upregulated genes showed the same pattern of dysregulation in the
prostate in our study (Table S3). Two of the 20 genes, Reep6 and
Dgat2, were downregulated in all four mouse models.
In the DU 145 human prostate cancer cell line, in which one
PTEN allele has been lost [42] and KLF5 expression is rather low[10], RNA-Seq and data analysis showed that ectopic expression of
KLF5 or the acetylation-deficient K369R mutant of KLF5 changed
the expression of many genes [24]. Seven of the 65 KLF5-regulated
genes (39 up and 26 down) and 54 K369R-regulated genes were also
dysregulated by Klf5 deletion in mouse prostates (Table S4). The
CHGA gene, which encodes a neuroendocrine differentiation marker
associated with higher Gleason score in human prostate cancer [43],
was the only gene that was downregulated by Klf5 deletion and
K369R expression but upregulated by KLF5 expression, suggesting
an up-regulation by acetylated KLF5.
Functional Processes and Molecular Pathways Modulated by
Klf5 Deletion in Pten-Null Mouse Prostates
To explore the molecular mechanisms underlying Klf5 deletion–
promoted tumorigenesis in Pten-null mouse prostates, we uploaded
the 1197 differentially expressed genes to the MetaCore platform to
enrich genes by diseases and identify significant GO processes,
signaling pathways, and molecular networks that are dysregulated by
Klf5 deletion.
Using the “Disease (by biomarker)” enrichment of the MetaCore
program, we first collected all the genes that were associated with the
disease of “prostate neoplasms”, which included 586 genes. Searching
the PubMed database with a gene name and “prostate cancer” as
keywords for these 586 genes revealed that 203 of themhad been reported
in at least one publication on prostate cancer. On the basis of the
publications, 104 of the 203 genes were positively associatedwith prostate
cancer, as indicated by a promoting effect on various behaviors and up-
regulation or DNA hypomethylation in prostate cancer cells; 68 of the
203 genes were negatively associated with prostate cancer, as indicated by
an inhibitory effect on cancer cell behavior and down-regulation or DNA
hypermethylation in cancer cells (Table S5 and Figure S2), and the
remaining 31 of the 203 genes had inconclusive information. Deletion of
Klf5 upregulated 70 of the 104 (67%) genes positively associated with
Figure 4. Knockout of Klf5 disrupts the architecture of prostate tumors induced by Pten deletion. Expression of basal cell markers Ck5, Ck14,
and p63, luminal cell marker Ck18, and smooth muscle marker Sma was detected by IHC staining (A) or IF staining (B and C) in consecutive
tissue sections (panel A only) ofmouse prostates at 6months of age. Pictures of basal and luminalmarkerswere taken from the same area of
tissue for better comparison (panel A only). DAPI staining was used to show nuclei (blue). Gene deletion status is indicated at the top and
marker names at the left. The magnification for images of basal and luminal markers is ×200, and two magnifications are shown for Sma
(×10 in the upper and ×40 in the lower). + and − indicate the presence and absence of a Klf5 or a Pten allele.
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Figure 5. Bioinformatic identification and analysis of Klf5 deletion–dysregulated prostate cancer–related genes andmolecular pathways in
Pten-null mouse prostates. (A and B) Validation of differential expression for 13 upregulated (A) and 20 downregulated genes by real-time
RT-PCR using the prostate samples including those used for microarray. White and black bars indicate microarray data and RT-PCR data,
respectively. *P b .05; **P b .01. (C) Heat map of genes with N2.0-fold expression change between wild-type and Klf5-null mouse
prostates and associated with prostate cancer based on PubMed publications. The four wild-type prostates and the four Klf5-null
prostates were randomly paired for map drawing. Genes are clustered on the basis of their association with prostate cancer, with those
positively affecting prostate cancer cell behavior or upregulated in prostate cancer marked as “positive”, and those negatively affecting
prostate cancer behavior or downregulated in prostate cancer marked as “negative”. The number in the parentheses after each gene
name indicates the number of PubMed publications available on that gene. The percentage of upregulated or downregulated genes is
shown. (D) Klf5 deletion activates canonical mitogenic signaling pathway involving AKT and ERK, as revealed by the analysis of Klf5
deletion–dysregulated genes using the MetaCore program. Up-regulation of signal initiating growth factors, cytokines, chemokines, and
receptors activates downstream effectors involved in different processes through multiple canonical signaling pathways. Different
shapes of the nodes represent functional classifications of genes. Red and blue circles in the nodes indicate up-regulation and down-
regulation, respectively, of genes. Lines between every two nodes indicate their interactions, with red for inhibition, green for activation,
gray for unspecified interaction, and dashed for indirect interaction. Arrow indicates the direction of a regulation.
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Table 2. Key Molecules Potentially Cooperating with Klf5 to Mediate Klf5 Deletion–Promoted Tumorigenesis, as Identified by the Network Analysis of MetaCore with Klf5 Deletion–Dysregulated
Genes, and Those Differentially Expressed Genes that Are Also Direct Transcriptional Targets of These Key Molecules
Key Molecules Genes Regulated by Klf5 Deletion
CREB1 Upregulated: Spp1, Tac1, Slc1a2, Egf, Ccnd2, Arg2, Msr1, Sstr2, Rgs2, Il1a, Gja1, Gzmb, Sfrp1, Selp, Vcam1, Cck, Tgm1, Il1b, Pfkfb3, Rgs1,
Spry2, Mat2a, Pgf, and Map2. Downregulated: Ldlr, Bhlhe40, Zfp667, Avpi1, Pmaip1, Bcl2, Ndn, Cdo1, Ppp2r2b, Kcnh2, Kcne4, Cd14,
Ppargc1b, Pparg, Agt, Chga, Muc4, Fam3b, Muc5b, and Ptges.
SP1 Upregulated: Crabp1, Abo, Cbs, Spp1, Slc9a2, Bhlha15, Chil1, Ccl20, Ccnd2, Padi2, Nkx3-1, Cyp7b1, Klf8, Prlr, Trf, Ednrb, Raver2, Sstr2,
Slc6a2, Ggt1, Tnc, Fbn1, Rgs2, Anxa6, Il1a, Serpina1a, Gja1, Bmp7, Serpina3n, Cd7, Pla2g7, Trem1, Crabp2, Selp, Vcam1, Cad, Pdgfd, Cck,
Pdgfrb, Mgst1, Soat1, Tnnt2, Tgm1, Col1a1, Col1a1, Timp1, Kcnj2, Flt1, Col1a2, Col1a2, Aqp1, Slc5a8, Gstm7, Adm, Slc19a2, Apln, Col4a2,
Angpt2, Spry2, Itgax, Mat2a, Ctns, Hdc, Padi3, Pdgfb, Fcgr4, Slc11a1, Aox1, Col4a1, Hhex, Nrp1, Cited2, Mgarp, Tfpi2, Phgdh, Mir365-1,
Tlr13, and Eng. Downregulated: Stard3, Hcn2, Atp6ap2, Ldlr, Idh2, Mbp,
Adam23, Cdkn2c, Bhlhe40, Cyp21a1, Zfp667, Ggh, Akap12, Cdk6, Noxo1, Cdh2, Atp4a, Efnb2, Bcl2, Ppl, Tnxb, Ppp2r2b, Ascl1, Kcnh2,
S100a6, Smpd3, F3, Acacb, Mst1r, Cd14, Tmprss2, Klf5, Tnfsf10, Napepld, Upk1b, Chga, Cyp2f2, Ces1d, Clcn2, Hpse, Muc4, Kcnq1, Gpc3,
Muc5b, Scnn1a, Krt7, Atp2a3, Ctse, Muc1, Ptges, Ltf, Hsd11b2, and Tff3.
MYC Upregulated: Cbs, Spp1, Ccnd2, Fah, Ak4, Eif4ebp1, Bmp7, Sfrp1, Lox, Vcam1, Cad, Cck, Pdgfrb, Mgst1, Jag2, Adm, Rgs1, Itgax, Mt1, Cdh3,
Sema6a, Angptl4, Slc11a1, Ndrg1, Cited2, Slc16a1, Bnip3, Spred2, and Alb. Downregulated: Mcm6, Abcd3, Vav2, Wnt5a, Ggh, Pmaip1, Rad51b,
Cdk6, Nans, Bcl2, Mir200a, Peg10, Apol7a, Itpr2, Hmgcs2, Camk1d, Golm1, Rasgef1a, Gldc, Mir429, Casp1, Wnt4, Ppargc1b, Sestd1, Sox2,
Pparg, Fa2h, Gpc3, and Hsd11b2.
ER Upregulated: Ttr, Spp1, Ugt2b35, Erbb4, Slc1a2, Plod2, Cyp7b1, Prlr, Trf, Ccl28, Stc2, Sstr2, Mme, Mir181b-1, St3gal4, Gja1, Fam132a, Bmp7,
Serpina3n, Thbs2, Cad, Rab31, Flt1, Aqp1, Adm,
Pfkfb3, Mir181b-2, Cdh3, Adamts9, Padi3, Abtb2, Fcgr4, Mgarp, and Lamb1. Downregulated: Fabp6, Abcd3, Bcas1, Anxa3, Rap1gap, Cobl, Foxc1,
Pmaip1, Mcf2l, Sytl2, Rad51b, Cdk6, Klf10, S100a6, Agr2, Mall, F3, Wnt4, Spire2, Por, Rapgefl1, Galnt4, Hsh2d, Agt, Ret, Sult1e1, Elf3, Gsta4,
Krt7, Atp2a3, Muc1, Ptges, Ltf, Cyp2b10, Krt4, Tff3, and Psca.
AR Upregulated: Spp1, Slc9a2, Ugt2b35, Azgp1, Ank, Nrn1, Nkx3-1, Pycr1, Mme, Eppin, Steap4, Cxcl2, Efna3, Pdgfrl, Slc19a2, Osbpl1a, Cxcl1, Gpr153,
Cdh3, Angptl4, Ndrg1, Nrp1, and Cited2. Downregulated: AA986860, Pmaip1, Cdh2, Rab3b, Ppfibp2, Peg10, Agr2, F3, Mir31, Tmprss2, Klf5, Sox2,
Pparg, Sult1e1, Scnn1a, Krt7, Muc1, and Psca.
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associated with prostate cancer, which is consistent with the heat map
generated by the R program using the 172 genes and their expression fold
changes (Figure S2). The expression fold change was greater than 2 for 58
of the 172 (34%) genes. For these 58 genes, 35 and 23were positively and
negatively, respectively, associated with prostate cancer. Twenty-six of the
35 (74%) positively associated genes were upregulated, while 17 of the 23
(74%) negatively associated genes were downregulated by Klf5 deletion,
which is obvious in the heat map for this group of genes (Figure 5C) and
consistent with a tumor suppressor function of Klf5.
The GO analysis of the MetaCore program also identified a
number of functional processes that were regulated by Klf5 deletion,
including some that are associated with tumorigenesis: blood vessel
morphogenesis, cell adhesion, extracellular matrix (ECM) remodel-
ing, EMT, chemotaxis, and inflammation (Table S6). Klf5 deletion
also altered a number of canonical signaling pathways, as revealed by
the pathway analysis function of the MetaCore program based on
functional processes (Table S7). Consistent with a tumor suppressor
function of Klf5, many of the pathways were activated by Klf5
deletion and their activation was shown to enhance multiple
tumorigenesis-related processes such as mitogen-activated protein
kinases (MAPK) cascades, EMT, G-protein signaling, and chemo-
taxis, including extracellular growth factors such as EGF, PDGF-B,
and PDGF-D; cell membrane tyrosine kinase receptors such as
ERBB4 and PDGFRβ; cytokine interleukin 1 (IL-1); and chemo-
kines and chemokine receptor such as CXCL1, CXCL2, CXCR2,
and so on (Table S7). These nine molecules are all located at the
originating point of specific signaling pathways, and their expression
changes could thus drive cascades of signaling changes. We applied
the “batch search” program of MetaCore to these nine genes and used
MetaCore’s “expand by one interaction” algorithm with all 1197 Klf5
deletion–dysregulated genes as “activated experiment” data to build
networks and identify overconnected pathways that are most relevant
to Klf5 deletion. Among the overconnected pathways identified, six
were most overconnected, including AKT, ERK, nuclear factor-
kappa B (NF-κB), protein kinase Cβ, p38, and peroxisomeproliferator-activated receptor gamma (PPARγ). Of all the pathways
identified in Table S7, AKT and ERK appeared in 12 and 11 of them,
respectively, whereas NF-κB, protein kinase Cβ, p38, and PPARγ
appeared in 5, 4, 3, and 1 of them, respectively.We therefore focused on
AKT and ERK to draw the pathway map of molecules that were
dysregulated by Klf5 deletion, including the nine signal initiation
molecules and some of their downstream effectors (p18, cyclin D2,
Spp1, S6, and 4E-BP1). Molecules that were between an initiating
molecule and an effector and not affected by Klf5 deletion were
eliminated from the map, resulting a schematic pathway map that
suggests that Klf5 deletion activates AKT and ERK signaling in the
regulation of cell cycle, invasion, and protein synthesis (Figure 5D).
In addition to the canonical pathways affected by Klf5 deletion
(Table S7 and Figure 5D), there could be novel networks affected by
Klf5 deletion. We therefore built molecular networks involving Klf5
deletion–dysregulated genes with the network analysis algorithm of
MetaCore. Networks with 50 total nodes and N4 seed nodes
(differentially expressed genes) were considered instructive and
meaningful. Among the 25 networks built, 20 centered around
cAMP responsive element binding protein 1 (CREB1), 2 centered
around SP1 (ranked the first and third based on P values), and one each
centered on Myc and RhoA (Figure S3). Similarly, 21 transcription
factor–centered networks were also identified, of which CREB1 and
SP1 were the first and second most significantly involved, while
estrogen receptor (ER), Myc, and androgen receptor (AR) ranked third,
fourth, and fifth, respectively (Table S8). These fivemolecules (CREB1,
SP1, Myc, ER, and AR) and the Klf5 deletion–dysregulated genes that
are directly regulated by these molecules are listed in Table 2.
EGF Was Dramatically Upregulated by Klf5 Deletion in the
Pten-Null Background
Whereas multiple growth factors and cytokines were significantly
upregulated by Klf5 deletion in the microarray experiment, the Egf
showed the highest fold change (2.97-fold). Considering the well-
established role of EGF and its downstream signaling in cell
proliferation and tumorigenesis, we performed additional experiments
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was performed with DP samples (6 months old, eight samples for each
of the three Klf5 genotypes, including the four with wild-type or Klf5-
null genotype used in microarray hybridization), and up-regulation of
Egf by homozygous deletion of Klf5 was confirmed in the Pten-null
background (Figure 6A). Hemizygous deletion of Klf5 did not show an
effect though (Figure 6A). We also detected Egf protein by IHC
staining in the same samples used for RNA detection and obtained
consistent results: Egf protein showed an evident increase in Klf5-null
prostates but no change in prostates with hemizygous deletion of Klf5
(Figure 6B). We further tested the effect of KLF5 on EGF expression in
the context of PTEN using the PNT2 human prostate luminal cell line,
in which proliferation signaling is activated by SV40 [44]. RNA
interference was applied to knock down KLF5 and/or PTEN, and the
knockdown effect was confirmed byWestern blot analysis (Figure 6C).
Real-time RT-PCR demonstrated that, while knockdown of PTEN
alone did not cause an apparent change in EGF expression, knockdown
of KLF5 significantly increased EGF mRNA level (P b .01), and the
increase was further enhanced by the knockdown of PTEN (P b .02)
(Figure 6D). We then examined whether Egf up-regulation by Klf5
deletion in Pten-null mouse tumors has a functional effect bymeasuring
the activity of Egfr. IHC staining demonstrated that the Y1068
phosphorylation of Egfr, an indication of Egfr activity [45], was clearly
increased in Klf5-null prostates (Figure 6E), indicating that Klf5
deletion further enhances the EGF/EGFR/MAPK signaling activity.
Deletion of Klf5 Increased Cell Proliferation with Consistent
Changes in the Expression of Proliferation-Related Molecules
On the basis of the findings that Klf5 deletion significantly increased
the size of Pten deletion–induced tumors (Figure 3), cell proliferation is
increased by Pten deletion alone [5]. We determined whether Klf5
deletion causes more cells to proliferate. Expression of the Ki67
proliferation marker was determined by IHC staining in each of the
prostate lobes, and the rate ofKi67 positivity in tumor cells was calculated.
While Klf5 hemizygous deletion did not cause an obvious change in the
rate of Ki67-positive cells, Klf5 homozygous deletion significantly
increased the rate (Figure 7A), indicating that homozygous deletion of
Klf5 increases cell proliferation in Pten deletion–induced prostate tumors.
Our microarray analyses indicated that Klf5 deletion increased the
expression of genes positively associated with prostate cancer
behaviors, activated mitogenic signaling pathways including AKT
and ERK signaling pathways, and enhanced the EGF/EGFR signaling
(Figures 5, C and D, and 6, A, B, and E). Loss of PTEN enhances
PI3K/AKT signaling [46] to increase cell proliferation, KLF5 has
been linked to Ras/MAPK proliferation signaling [20,22], and loss of
KLF5 downregulates the p15 cell cycle inhibitor in the context of
transforming growth factor–β (TGF-β) [38,47]. We therefore
evaluated the expression of key players in the PI3K/AKT signaling
pathway including phosphorylated Akt (p-Akt), phosphorylated
Erk1/2 (p-Erk1/2), phosphorylated mTor (p-mTor), phosphorylated
S6 (p-S6), and p15 cell cycle inhibitor by IHC staining and Western
blot analysis in Pten-null prostate tumors at 6 months of age. While
hemizygous deletion of Klf5 mildly increased the expression of p-Akt
and p-S6, homozygous deletion of Klf5 led to much more dramatic
increases in their expression (Figure 7, A and B), indicating that Klf5
deletion significantly enhances the effect of Pten deletion on PI3K/
Akt signaling. Expression of p-Erk1/2 showed a similar pattern, with
a much greater increase by Klf5 homozygous deletion than that by
Klf5 hemizygous deletion (Figure 7, A and B). These results supportthe findings from MetaCore’s pathway analysis. For p15, hemizygous
deletion of Klf5 decreased nuclear staining, and homozygous deletion
of Klf5 led to a more significant decrease in p15 expression (Figure 7,
A and B). Although mTor is one of the crucial players in PI3K/Akt
signaling, we were unable to detect p-mTor by Western blot analysis
and detected few cells that were positive in IHC staining for p-mTor
in Klf5-null tumors (Figure S4), suggesting that p-mTor is less
relevant in Klf5-null tumors.
Discussion
Klf5 Deletion Promotes PtenDeletion–Induced Prostatic Tumorigenesis
The current literature is somewhat inconsistent about the function
of KLF5 in tumor development. On the one hand, KLF5 promotes
tumor growth in xenograft models [19,48], is necessary for intestinal
tumorigenesis in genetically modified mice [49], and mediates Ras
activation–induced intestinal tumorigenesis [22,23]. On the other
hand, KLF5 can also suppress tumorigenesis in xenograft models
[18,50]. Using a tissue-specific knockout mouse model, which
provides more definitive evidence for the function of a given tumor
suppressor gene, we were able to prove the tumor suppressor activity
of KLF5. For example, in mouse prostates with hemizygous deletion
of Pten, which develop mPIN [5], simultaneous deletion of Klf5
shortened the latency of mPIN development and caused more severe
phenotypic alterations in the mPIN (Figure 2). When both Pten
alleles were deleted, which alone causes prostate cancer [5], Klf5
deletion caused more rapid tumor growth and more severe
phenotypic and molecular alterations in cancer (Figures 3–7).
In various human cancers including prostate cancer, deletion of
the KLF5 locus is the second most frequent chromosomal deletion,
occurring in about 42% of tumors [9,51]. KLF5 is also inactivated in
more than 20% of human cancers through excess protein
degradation mediated by the amplification and overexpression of
the WWP1 oncogenic ubiquitin E3 ligase [15,52–54]. The
establishment of a tumor-promoting effect of Klf5 deletion in this
study suggests that KLF5 inactivation could impact more than half of
human cancers.
While Klf5 deletion clearly promoted the development of prostate
cancer initiated by Pten deletion (Figures 2 and 3), our previous study
indicated that deletion of Klf5 alone in prostatic epithelial cells does
not have a pro-tumorigenic effect [25], as hemizygous deletion of
Klf5 caused hyperplasia with increased cell proliferation but did not
cause neoplasms, and homozygous deletion of Klf5 induced apoptosis
without causing detectable cell proliferation [25]. Multiple genetic
events are usually necessary for a tumor to form and progress, and it
appears that at least another oncogenic event, such as Pten deletion, is
necessary to release the pro-tumorigenic effect of Klf5 deletion.
In human prostate cancer, a number of chromosomal regions are
deleted or amplified, and deletions of NKX3-1 at 8p21, KLF5 at
13q21, and PTEN at 10q23 are among the most common deletions
[1], and at least some prostate cancers possess the deletions of both
KLF5 and PTEN loci. For example, the LNCaP prostate cancer cell
line has a 2-bp homozygous deletion of PTEN [29] and a hemizygous
deletion of KLF5 [10], and prostate cancer xenografts PC82 and
LuCaP 58 have loss of both PTEN and KLF5 loci [10,55–57]. Our
findings in this study thus establish a positive interaction between
KLF5 and PTEN deletions in prostatic carcinogenesis. They also
provide a mouse model of prostate cancer involving two common
genetic alterations in human prostate cancer.
Figure 6. Klf5 deletion upregulates EGF in Pten-null mouse prostate tumors and human prostate epithelial cell line. (A, B, and E) Detection
of EGF mRNA expression by real-time RT-PCR (A) and Egf and p-Egfr proteins by IHC staining (B and E) in 6-month-old Pten-null mouse
DPs with indicated Klf5 deletion status. Data for each genotype in A was from eight mice. (C and D) Detection of protein expression of
KLF5 and PTEN by Western blot analysis (C) and mRNA expression of KLF5, PTEN, and EGF by real-time RT-PCR (D) in the PNT2
immortalized human prostate luminal epithelial cell line with the knockdown of KLF5, PTEN, or both by RNA interference.
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described above, Pten deletion also interacts with Nkx3-1 deletion in
prostatic carcinogenesis [58,59]. Deletions of Klf5 and Nkx3-1,
however, do not appear to have an additive effect [60]. PTEN is an
inhibitor of the PI3K/AKT signaling pathway, and PTEN loss leads
to increased PI3K/AKT signaling activities that enhance both cell
proliferation and survival [27,61].
While homozygous deletion of Klf5 alone increases cell death at least at
age 18months, as demonstrated in our previous study [25], it did not show
a similar effect in Pten-null prostate tumors at 6 months of age (Figure S5);
it rather enhanced cell proliferation significantly in these tumors
(Figure 7A). It is well established that Pten loss leads to the activation of
the PI3K/AKT signaling, which is pro-survival [62,63]. It is thus possible
that enhanced survival by PI3K/AKT activation overcomes cell deathFigure 7.Molecular characterization of prostate tumors induced by Klf
oncogenic kinases p-Akt, p-Erk1/2, and p-S6, and the p15 cell cycle i
deletion status of Klf5 and Pten. Marker names are indicated at the le
(%) of Ki67-positive cells, as determined by cell counting, is shown
Detection of protein expression for Klf5, p-Akt, Akt, p-Erk1/2, Erk1/2, p
anterior mouse prostates with the same genotype and age used in A. R
and statistical significance was evaluated by using Student’s t test.
genes is indicated at the top. + and − indicate the presence and abinduced by Klf5 homozygous deletion, thus unmasking the tumor-
promoting effect of Klf5 homozygous deletion by activating multiple
oncogenic signaling pathways including those described in our recent study
[24]. The samemechanism could apply to other tumor suppressors that are
part of the TGF-β signaling pathway and whose deletions have a positive
interaction with Pten deletion in tumor development, including Smad4
and p27 [8,64]. Furthermore, it is possible that other signaling pathways
that prevent cell death could also unmask pro-tumorigenic functions of
Klf5 deletion, which remains unexplored.
Klf5 Deletion Promotes the Luminal but Attenuates the Basal
Type of Pten Deletion–Induced Prostate Tumor Cells
Most human prostate cancers have a luminal phenotype, and very
few (b1%) human prostate cancer cells express basal cell markers5 and Pten deletion. (A) IHC staining of the Ki67 proliferationmarker,
nhibitor in tissue sections of APs at 6 months of age with different
ft, and the deletion status of genes is indicated at the top. The ratio
at the lower right corner of each image of the Ki67 panels. (B)
-S6, p15, and β-actin by Western blot analysis in tissue lysates from
elative protein level was determined by using the ImageJ software,
Marker names are indicated at the left, and the deletion status of
sence of an allele for Klf5 and Pten. *P b .05; **P b .01.
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can be transformed to give rise to prostate cancer [66]. In Pten deletion–
induced mouse prostate tumors, the basal cell population is expanded to
the acinus with an increased expression of the prostate stem cell antigen
(PSCA) transient amplifying cell marker [5,39,67], indicating a more
profound promoting effect of Pten deletion on basal cells during
tumorigenesis. Unexpectedly, Klf5 deletion reversed the effect of Pten
deletion on the ratio of basal to luminal cells in prostate tumors. While
Klf5 deletion significantly increased the number of luminal tumor cells,
which could be due to increased proliferation of this type of cells as
indicated by the percentage of Ki67-expressing cells (Figure 7A), it
actually diminished the number of basal tumor cells, as indicated by Ck5
expression (p63−), in the cancerous acini (Figure 4B). Basal cells in the
basal layers, as identified by p63 expression, were not affected (Figure 4C).
Therefore, the tumor-promoting effect of Klf5 deletion appears to be
restricted to luminal tumor cells. Whereas the increase in the luminal to
basal ratio by Klf5 deletion could result from the differentiation of Pten
deletion–induced Ck5+/p63− TA cells, it is more likely thatKlf5 deletion
causes the death or prevents the proliferation of Ck5+/p63− TA cells,
because these cells were almost absent in cancerous acini (Figure 4C) and
the expression of the PSCAmarker for such cells was dramatically reduced
(more than 80-fold) on Klf5 deletion (Figure 5, B and C, and Table S2).
Another possibility is that Klf5 deletion prevented the differentiation of
p63+/Ck5+ cells in the basal layer into Ck5+/p63− TA cells. To fully
address whether Klf5 deletion has different effects on basal and luminal
cells, it is necessary to perform additional studies using approaches such as
lineage tracing and luminal or basal cell–specific Cre mice.
In normal prostates, our previous study suggests that Klf5 could also
have different or even opposing functions in basal and luminal cells [25].
For example, whereas Klf5 is expressed in both luminal and basal cells, the
protein is typically acetylated in luminal cells (AcKlf5) while unacetylated
in basal cells (unAcKlf5) [25], and AcKLF5 and unAcKLF5 suppress and
promotes, respectively, cell proliferation and tumor growth [24,38].
Taken together with the different effects of Klf5 deletion on luminal and
basal tumor cells, we propose that unAcKLF5 is necessary for basal cell
proliferation and AcKLF5 is necessary for luminal differentiation. We
further propose that Klf5 deletion compromises the pro-differentiation
function of AcKLF5, leading to partial dedifferentiation and subsequent
proliferation of luminal cells while attenuating the proliferation or
survival of basal cells in Pten-null prostates. We are currently testing these
predictions by developing a mouse model in which acetylation-deficient
Klf5 replaces wild-type Klf5 in the prostate.
Klf5 Deletion Promotes Cancer Cell Proliferation by
Multiple Mechanisms
In understanding how Klf5 deletion promotes Pten deletion–
initiated prostatic tumorigenesis, microarray-based expression profil-
ing and molecular pathway/network analysis indicated that a large
number of genes involved in a number of molecular signaling
pathways are dysregulated by Klf5 deletion. One significant group of
upregulated molecules included extracellular growth factors EGF and
PDGFs, cytokine IL-1, chemokines CXCL and CCL, and tyrosine
kinase and chemokine receptors ERBB4, PDGFR, and CXCR2
(Tables S2 and S7 and Figure 5). Egf, in particular, is downregulated
by Pten deletion alone [5] but was upregulated by Klf5 deletion in the
Pten-null background (Figures 5, A and C, and 6A). Up-regulation of
Egf protein and activation of Egfr by Klf5 deletion were also detected
by IHC staining in mouse prostates (Figure 6, B and E). Consistently,
in the PNT2 human prostate epithelial cell line, knockdown ofPTEN alone slightly downregulated but knockdown of KLF5 alone
or in combination with PTEN knockdown significantly regulated
EGF mRNA expression (Figure 6D). EGF is a potent growth factor
that activates AKT and ERK signaling [68,69], further implicating
AKT and ERK in Klf5 deletion–promoted tumorigenesis. Up-
regulation of Egf by Klf5 deletion could therefore be one of the
driving factors underlying Klf5 deletion–promoted cell proliferation
and tumorigenesis. This possibility remains to be tested.
Taken together with previous observations that Pten deletion–initiated
mouse prostate tumors have an increased rate of cell proliferation due to
the activation of PI3K/AKT and MAPK signaling [5,27,61,70,71], we
determined the effects ofKlf5 deletion on cell proliferation and AKT and
ERK activities in Pten-null prostate tumors. When Klf5 was homozy-
gously deleted, the cell proliferation rate more than doubled (Figure 7A,
Ki67 panel), the expression of p-Akt and Erk were obviously increased
(Figure 7A), and the rate of cell death was unaffected (Figure S5).
Expression of activated Akt and Erk and their downstreammolecule p-S6
[27,72] was significantly increased, while p-mTor was slightly
upregulated. These results indicate that Klf5 deletion further promotes
the proliferation of tumor cells, and an enhanced PI3K/AKT mitogenic
signaling pathway is involved. KLF5 itself directly regulates the p15 cell
cycle inhibitor in cell proliferation [38,47], and this mechanism also
appeared to function in Pten and Klf5-null prostate tumors, where Klf5
deletion led to decreased p15 expression in a dose-dependent manner
(Figure 7, A and B). Therefore, Klf5 deletion likely mediates more rapid
tumor growth by multiple pro-proliferative molecular pathways.
In a previous study, homozygous deletion of Pten in mouse
prostates induced invasive adenocarcinoma and subsequent
metastasis to the lymph node and lung at 4 months of age [5]. In
our study, however, no tumor invasion, based on Sma staining, or
metastasis, based on the dissection of lungs and livers, was evident
in mice carrying Pten- and Klf5-null tumors even at 6 months of
age. However, Klf5 deletion could still promote tumor invasion
and metastasis. For example, Klf5 deletion led to a thinner or
discontinuous smooth muscle layer (Figure 4) and the up-
regulation of multiple matrix metalloproteinases, including
MMP-12, MMP-13, and MMP-8 (Figure 5A and Table S2). In
addition, Klf5 deletion also upregulated Spp1, one of four signature
molecules predictive of prostate cancer metastasis [8], and KLF5
inactivation promoted EMT, a strong indicator of tumor invasion
and metastasis, by downregulating miR-200 micro-RNAs [73].
Klf5 deletion also downregulated miR-200 genes in mouse prostates
(Tables S2, S6, and S7). Therefore Klf5 deletion could still promote
tumor invasion and metastasis, and the lack of metastasis in this study
could be caused by multiple reasons, including insufficient time for
tumor progression and variation in genetic background among different
mouse strains.
Multiple Molecules Could Cooperate with Klf5 in Gene Regulation
Despite the fact that KLF5 functions in a variety of pathophys-
iological processes in a context-dependent manner in various tissues
[24,38,51], a large number of the same genes dysregulated by Klf5
deletion in mouse prostate tumors were also regulated by KLF5 or its
acetylation-deficient mutant K369R in xenograft tumors of the DU
145 human prostate cancer cell line (Table S4). A large number of the
same genes were also dysregulated by Klf5 deletion across multiple
types of tissues including cornea, villus, and bladder (Table S3),
suggesting that there is a common set of genes that is regulated by
Klf5 in different tissues or under different contexts.
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deletion using the Klf5 deletion–dysregulated genes, we found
that CREB1, SP1, and Myc were the most significantly affected
(Figure S3 and Table 2), all of which are transcription factors.
Network analysis for transcription factors identified five
transcription factors that most significantly related to Klf5
deletion–dysregulated genes, and CREB1, SP1, and Myc were
again among the five. The other two transcription factors among
the top 5 were ER and AR (Tables 2 and S8). Interestingly, the
same five transcription factors were also identified as the most
relevant molecules to the function of KLF5 and K369R in the
DU 145 human prostate cancer cell [24]. It is thus possible that,
as a transcription factor, KLF5 cooperates with CREB1, SP1,
Myc, ER, and AR, e.g., in a transcription complex, to maintain
the normal homeostasis of prostate epithelium, and disruption of
this complex could promote tumorigenesis.
Some published studies support this possibility. For example,
in human prostate cancer cells, KLF5 has been demonstrated to
suppress tumor growth by forming a transcriptional complex
with CREB1 and ERβ to upregulate the FOXO1 tumor
suppressor gene [18]. Phosphorylation of CREB1 is a classic
mechanism of CREB1 activation [74], so it is worth testing
whether CREB1 phosphorylation affects KLF5 function. ERα
has also been shown to physically interact with KLF5 in gene
regulation and cell proliferation in ERα-positive breast cancer cells
[75]. Sp1 and KLF5 belong to the same family of Krüppel-like
factors that bind to GC-rich promoter elements [76], so they may
both bind to promoters of the same genes to cooperate, although
this idea has not been tested. For Myc, not only is its gene
transcription directly regulated by KLF5 [77], it also directly
interacts with KLF5 in a TGF-β–dependent manner to regulate cell
proliferation [47]. AR is essential for both the normal development
and function of the prostate gland and the growth of prostate cancer
[78]. Although it is unknown whether AR and KLF5 form a
complex, some molecules including Smad3 and p300 have been
demonstrated to physically interact with both AR [79,80] and
KLF5 [47]. It is worth testing whether and how KLF5 cooperates
with CREB1, Sp1, Myc, ER, and AR in gene regulation in
epithelial homeostasis.
In summary, we examined the effects of Klf5 deletion on Pten
deletion–initiated prostatic tumorigenesis in genetically modified
mice and found that Klf5 deletion promoted the development and
increased the severity of Pten deletion–induced mPIN and prostate
tumor. Interestingly, Klf5 deletion increased the ratio of Ck18-
positive luminal tumor cells to Ck5-positive basal tumor cells in
tumors, suggesting a restricted promoting effect of Klf5 deletion on
luminal tumor cells. Klf5 deletion in Pten-null prostate tumors
increased the cell proliferation rate, which involved multiple signaling
pathways including the up-regulation of growth factor EGF,
activation of PI3K/AKT and MAPK, and the inactivation of the
p15 cell cycle inhibitor. Further pathway analysis suggests that KLF5
cooperates with other transcription factors including CREB1, Sp1,
Myc, ER, and AR to regulate gene expression in the prostate.
These findings validate the tumor suppressor function of KLF5 in
genetically modified mice and also provide a mouse model that shares
two common genetic alterations with human prostate cancer,
deletions of PTEN and KLF5.
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